Современные возможности местной терапии угревой болезни
Современные возможности местной терапии угревой болезни
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence
and in adults. BMJ 1979; 1: 1109–10.
2. Майорова С.А., Шаповалов В.С., Ахтямов С.Н. Угревая болезнь в
практике врача-дерматокосметолога. М.: Фирма Клавель, 2005;
6–85.
3. Picardi A, Abeni D, Melchi CF et al. Psychiatric morbidity in dermatological
outpatients: an issue to be recognized. Br J Dermatol 2000; 143:
983–91.
4. Mallon E, Newton JN, Klassen A et al. The quality of life in acne: a
comparison with general medical conditions using generic questionnaires.
Br J Dermatol 1999; 140: 672–6.
5. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115: 386.
6. Gollnick HPM, Zouboulis CC, Akamatsu H et al. Pathogenesis and
pathogenesis-related treatment of acne. J Dermatol 1991; 18: 489–99.
7. Thiboutot D, Knaggs H, Gilliland H et al. Activity of 5-α-reductase and
17-α-hydroxysteroid dehydrogenase in the infraindibulum of subjects
with and without acne vulgaris. Dermatology 1998; 196: 38–42.
8. Thiboutot DM, Knaggs H, Gilliland K et al. Activity of type 1 5-α-
reductase is greater in the follicular infrainfundibulum compared with
the epidermis. Br J Dermatol 1997; 136: 166–71.
9. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators
of androgen homeostasis in human skin. J Invest Dermatol 2001; 116:
793–800.
10. Cunliffe WJ, Holland DB, Clark SM et al. Comedogenesis: some new
aetiological, clinical and therapeutic strategies. Br J Dermatol 2000;
142: 1084–91.
11. Webster GF, Leyden JJ, Musson RA, Douglas SD. Susceptibility of Propionibacterium
acnes to killing and degradation by human neutrophils
and monocytes in vitro. Infect Immun 1985; 49 (1): 116–21.
12. McGinley KJ, Webster GF, Ruggieri MR, Leyden JJ. Regional variations
in density of cutaneous propionibacteria: correlation of Propionibacterium
acnes with sebum secretion. J Clin Microbiol 1980; 12: 672–5.
13. Cove JH, Holland KT, Cunliffe WJ. An analysis of sebum excretion
rate, bacterial population and the production rate of free fatty acids on
human skin. Br J Dermatol 1980; 103: 383–6.
14. Leeming JP, Holland KT, Cunliffe WJ. The microbial colonization of
inflamed acne vulgaris lesions. Br J Dermatol 1988; 118: 203–8.
15. Jappe U, Ingham E, Henwood J, Holland KT. Propionibacterium
acnes and inflammation in acne; P. acnes has T-cell mitogenic activity.
Br J Dermatol 2002; 146: 202–8.
16. Wolf JE Jr, Kaplan D, Kraus SJ et al. Efficacy and tolerability of combined
topical treatment of acne vulgaris with adapalene and clindamycin:
A multicenter, randomized, investigatorblinded study. J Am
Acad Dermatol 2003; 49: S211–7.
17. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology
1998; 196: 119–25.
18. Thielitz A, Helmdach M, Ro? pke EM, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
19. Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical
retinoids: their uses in dermatology. Dermatol Clin 1993; 11: 107–15.
20. Hensby C, Cavey D, Bouclier M et al. The in vivo and in vitro antiinflammatory
activity of CD271: a new retinoid-like modulator of cell
differentiation. Agents Actions 1990; 29: 56–8.
21. Thielitz A, Helmdach M, Ro? pke EM, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
22. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne
vulgaris. Arch Dermatol 1969; 99: 469–76.
23. Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and
safety of adapalene gel 0,1% and tretinoin gel 0,025% in the treatment
of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34:
482–5.
24. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report
from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol
2003; 49 (1 suppl.): S1–S37.
25. Cunliffe WJ, Meynadier J, Alirezai M et al. Is combined oral and topical
therapy better than oral therapy alone in patients with moderate to
moderately severe acne vulgaris? A comparison of the efficacy and safety
of lymecycline plus adapalene gel 0,1%, versus lymecycline plus gel
vehicle. J Am Acad Dermatol 2003; 49 (suppl. 2): 18–26.
26. Ozolins M, Eady EA, Avery AJ et al. Comparison of five antimicrobial
regimens for treatment of mild to moderate inflammatory facial acne
vulgaris in the community. A randomized controlled trial. Lancet 2004;
364: 2188–95.
27. Thielitz A, Helmdach M, Rцpke E-M, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145 (1):
19–27.
28. Монахов С.А., Иванов О.Л., Самгин М.А. Антиандрогенная тера-
пия акне у женщин. Рос. журн. кожн. и венерол. бол. 2005; 3:
66–70.
29. Bordat P, Chesnoy S. Mixing glycolic acid with retinaldehyde: RALGA,
a technical achievement. Dermatology 2005; 210 (Suppl. 1): 2–5.
30. Tran C, Kasraee B, Grand D et al. Pharmacology of RALGA, a mixture
of retinaldehyde and glycolic acid. Dermatology 2005; 210 (Suppl. 1):
6–13.
31. Poli F, Ribet V, Lauze C et al. Efficacy and safety of 0,1% retinaldehyde/
6% glycolic acid (diacneal) for mild to moderate acne vulgaris. A
multicentre, double-blind, randomized, vehicle-controlled trial. Dermatology
2005; 210 (Suppl. 1): 14–21.
32. Аравийская Е.Р., Соколовский Е.В., Кирпичева А.А. и др. Место
новых средств для базового ухода, содержащих производные ви-
тамина А и гидроксикислоты, в ведении пациентов с акне. Клин.
дерматол. и венерол. 2006; 1: 53–8.
33. Dreno B, Nocera T, Verriere F et al. Topical retinaldehyde with glycolic
acid: study of tolerance and acceptability in association with antiacne
treatments in 1,709 patients. Dermatology 2005; 210 (Suppl. 1):
22–9.
34. Katsambas AD. RALGA (Diacneal), a retinaldehyde and glycolic acid
association and postinflammatory hyperpigmentation in acne--a
review. Dermatology 2005; 210 (Suppl. 1): 39–45.
35. Boisnic S, Branchet-Gumila MC, Nocera T, Verriere F. RALGA (Diacneal)
decreases melanin content in a human skin model. Dermatology
2005; 210 (Suppl. 1): 35–8.
36. Kasraee B, Tran C, Sorg O, Saurat JH. The depigmenting effect of
RALGA in C57BL/6 mice. Dermatology 2005; 210 (Suppl. 1): 30–4.
and in adults. BMJ 1979; 1: 1109–10.
2. Майорова С.А., Шаповалов В.С., Ахтямов С.Н. Угревая болезнь в
практике врача-дерматокосметолога. М.: Фирма Клавель, 2005;
6–85.
3. Picardi A, Abeni D, Melchi CF et al. Psychiatric morbidity in dermatological
outpatients: an issue to be recognized. Br J Dermatol 2000; 143:
983–91.
4. Mallon E, Newton JN, Klassen A et al. The quality of life in acne: a
comparison with general medical conditions using generic questionnaires.
Br J Dermatol 1999; 140: 672–6.
5. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115: 386.
6. Gollnick HPM, Zouboulis CC, Akamatsu H et al. Pathogenesis and
pathogenesis-related treatment of acne. J Dermatol 1991; 18: 489–99.
7. Thiboutot D, Knaggs H, Gilliland H et al. Activity of 5-α-reductase and
17-α-hydroxysteroid dehydrogenase in the infraindibulum of subjects
with and without acne vulgaris. Dermatology 1998; 196: 38–42.
8. Thiboutot DM, Knaggs H, Gilliland K et al. Activity of type 1 5-α-
reductase is greater in the follicular infrainfundibulum compared with
the epidermis. Br J Dermatol 1997; 136: 166–71.
9. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators
of androgen homeostasis in human skin. J Invest Dermatol 2001; 116:
793–800.
10. Cunliffe WJ, Holland DB, Clark SM et al. Comedogenesis: some new
aetiological, clinical and therapeutic strategies. Br J Dermatol 2000;
142: 1084–91.
11. Webster GF, Leyden JJ, Musson RA, Douglas SD. Susceptibility of Propionibacterium
acnes to killing and degradation by human neutrophils
and monocytes in vitro. Infect Immun 1985; 49 (1): 116–21.
12. McGinley KJ, Webster GF, Ruggieri MR, Leyden JJ. Regional variations
in density of cutaneous propionibacteria: correlation of Propionibacterium
acnes with sebum secretion. J Clin Microbiol 1980; 12: 672–5.
13. Cove JH, Holland KT, Cunliffe WJ. An analysis of sebum excretion
rate, bacterial population and the production rate of free fatty acids on
human skin. Br J Dermatol 1980; 103: 383–6.
14. Leeming JP, Holland KT, Cunliffe WJ. The microbial colonization of
inflamed acne vulgaris lesions. Br J Dermatol 1988; 118: 203–8.
15. Jappe U, Ingham E, Henwood J, Holland KT. Propionibacterium
acnes and inflammation in acne; P. acnes has T-cell mitogenic activity.
Br J Dermatol 2002; 146: 202–8.
16. Wolf JE Jr, Kaplan D, Kraus SJ et al. Efficacy and tolerability of combined
topical treatment of acne vulgaris with adapalene and clindamycin:
A multicenter, randomized, investigatorblinded study. J Am
Acad Dermatol 2003; 49: S211–7.
17. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology
1998; 196: 119–25.
18. Thielitz A, Helmdach M, Ro? pke EM, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
19. Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical
retinoids: their uses in dermatology. Dermatol Clin 1993; 11: 107–15.
20. Hensby C, Cavey D, Bouclier M et al. The in vivo and in vitro antiinflammatory
activity of CD271: a new retinoid-like modulator of cell
differentiation. Agents Actions 1990; 29: 56–8.
21. Thielitz A, Helmdach M, Ro? pke EM, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
22. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne
vulgaris. Arch Dermatol 1969; 99: 469–76.
23. Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and
safety of adapalene gel 0,1% and tretinoin gel 0,025% in the treatment
of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34:
482–5.
24. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report
from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol
2003; 49 (1 suppl.): S1–S37.
25. Cunliffe WJ, Meynadier J, Alirezai M et al. Is combined oral and topical
therapy better than oral therapy alone in patients with moderate to
moderately severe acne vulgaris? A comparison of the efficacy and safety
of lymecycline plus adapalene gel 0,1%, versus lymecycline plus gel
vehicle. J Am Acad Dermatol 2003; 49 (suppl. 2): 18–26.
26. Ozolins M, Eady EA, Avery AJ et al. Comparison of five antimicrobial
regimens for treatment of mild to moderate inflammatory facial acne
vulgaris in the community. A randomized controlled trial. Lancet 2004;
364: 2188–95.
27. Thielitz A, Helmdach M, Rцpke E-M, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145 (1):
19–27.
28. Монахов С.А., Иванов О.Л., Самгин М.А. Антиандрогенная тера-
пия акне у женщин. Рос. журн. кожн. и венерол. бол. 2005; 3:
66–70.
29. Bordat P, Chesnoy S. Mixing glycolic acid with retinaldehyde: RALGA,
a technical achievement. Dermatology 2005; 210 (Suppl. 1): 2–5.
30. Tran C, Kasraee B, Grand D et al. Pharmacology of RALGA, a mixture
of retinaldehyde and glycolic acid. Dermatology 2005; 210 (Suppl. 1):
6–13.
31. Poli F, Ribet V, Lauze C et al. Efficacy and safety of 0,1% retinaldehyde/
6% glycolic acid (diacneal) for mild to moderate acne vulgaris. A
multicentre, double-blind, randomized, vehicle-controlled trial. Dermatology
2005; 210 (Suppl. 1): 14–21.
32. Аравийская Е.Р., Соколовский Е.В., Кирпичева А.А. и др. Место
новых средств для базового ухода, содержащих производные ви-
тамина А и гидроксикислоты, в ведении пациентов с акне. Клин.
дерматол. и венерол. 2006; 1: 53–8.
33. Dreno B, Nocera T, Verriere F et al. Topical retinaldehyde with glycolic
acid: study of tolerance and acceptability in association with antiacne
treatments in 1,709 patients. Dermatology 2005; 210 (Suppl. 1):
22–9.
34. Katsambas AD. RALGA (Diacneal), a retinaldehyde and glycolic acid
association and postinflammatory hyperpigmentation in acne--a
review. Dermatology 2005; 210 (Suppl. 1): 39–45.
35. Boisnic S, Branchet-Gumila MC, Nocera T, Verriere F. RALGA (Diacneal)
decreases melanin content in a human skin model. Dermatology
2005; 210 (Suppl. 1): 35–8.
36. Kasraee B, Tran C, Sorg O, Saurat JH. The depigmenting effect of
RALGA in C57BL/6 mice. Dermatology 2005; 210 (Suppl. 1): 30–4.
Авторы
А.В.Миченко, А.Н.Львов
ГОУ ВПО Московская медицинская академия им. И.М.Сеченова Росздрава
ГОУ ВПО Московская медицинская академия им. И.М.Сеченова Росздрава
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.
